Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 3

2(25.0%)

Phase 1

2(25.0%)

8Total

Phase 2(4)

Phase 3(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07259538Phase 1Recruiting

A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray

Role: lead

NCT07136805Phase 3Not Yet Recruiting

A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

Role: lead

NCT06164743Phase 2Completed

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Role: lead

NCT06906198Phase 1Completed

Pharmacokinetics of VVN461 Ophthalmic Solution

Role: lead

NCT06679153Phase 2Completed

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

Role: lead

NCT06360133Phase 3Recruiting

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease

Role: lead

NCT05451329Phase 2Completed

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

Role: lead

NCT04556838Phase 2Completed

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

Role: lead

All 8 trials loaded